ArticleERJ open research2025
Validation of the modified BODE index using the activity domain of St George's Respiratory Questionnaire.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The traditional BODE (Body-mass Index, Obstruction, Dyspnoea and Exercise) index can be challenging in routine practice. This study introduced the modified BODE (mBODE) index that replaces the exercise component with the activity domain of the St. George's Respiratory Questionnaire (SGRQ). Our study aimed to evaluate its relationship with baseline clinical characteristics and its predictive performance for exacerbations and mortality compared to the original index. Methods: Data were extracted from the Korean COPD Subgroup Study cohort. The activity domain of the SGRQ was divided into quartiles, replacing the exercise component of the BODE index to define the mBODE index. Clinical outcomes were compared between quartiles of the BODE and mBODE indices. We analysed the associations of both scores with 1-year exacerbations and all-cause mortality. Results: This study enrolled 1765 individuals, and both scores were associated with moderate-to-severe and severe exacerbations. In the analysis of future exacerbation frequency, the Akaike information criterion (AIC) and log-likelihood values indicated that the mBODE index had better predictive performance than the BODE index in both models. In the analysis of the presence of future exacerbation, the AIC showed that the mBODE index had superior predictive performance compared to the BODE index. Furthermore, both indices predicted all-cause mortality in individuals with COPD (BODE: adjusted hazard ratio (aHR=2.53, p<0.001; mBODE: aHR=2.00, p<0.01). Conclusions: The mBODE index reflected the clinical characteristics and showed association with exacerbations and mortality comparable to those of the traditional BODE index.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.